KR101925125B1 - Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 - Google Patents

Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 Download PDF

Info

Publication number
KR101925125B1
KR101925125B1 KR1020160075024A KR20160075024A KR101925125B1 KR 101925125 B1 KR101925125 B1 KR 101925125B1 KR 1020160075024 A KR1020160075024 A KR 1020160075024A KR 20160075024 A KR20160075024 A KR 20160075024A KR 101925125 B1 KR101925125 B1 KR 101925125B1
Authority
KR
South Korea
Prior art keywords
nckap1
cancer
expression level
protein
colon cancer
Prior art date
Application number
KR1020160075024A
Other languages
English (en)
Korean (ko)
Other versions
KR20170141951A (ko
Inventor
최은경
정성윤
송시열
이재희
Original Assignee
울산대학교 산학협력단
재단법인 아산사회복지재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울산대학교 산학협력단, 재단법인 아산사회복지재단 filed Critical 울산대학교 산학협력단
Priority to KR1020160075024A priority Critical patent/KR101925125B1/ko
Priority to PCT/KR2017/006326 priority patent/WO2017217807A2/fr
Publication of KR20170141951A publication Critical patent/KR20170141951A/ko
Application granted granted Critical
Publication of KR101925125B1 publication Critical patent/KR101925125B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020160075024A 2016-06-16 2016-06-16 Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 KR101925125B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020160075024A KR101925125B1 (ko) 2016-06-16 2016-06-16 Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
PCT/KR2017/006326 WO2017217807A2 (fr) 2016-06-16 2017-06-16 Biomarqueur comprenant la nckap1 en tant qu'ingrédient efficace pour le diagnostic du cancer colorectal ou pour la prédiction de métastases et le pronostic du cancer colorectal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160075024A KR101925125B1 (ko) 2016-06-16 2016-06-16 Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물

Publications (2)

Publication Number Publication Date
KR20170141951A KR20170141951A (ko) 2017-12-27
KR101925125B1 true KR101925125B1 (ko) 2018-12-04

Family

ID=60664553

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160075024A KR101925125B1 (ko) 2016-06-16 2016-06-16 Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물

Country Status (2)

Country Link
KR (1) KR101925125B1 (fr)
WO (1) WO2017217807A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200117913A (ko) * 2019-04-05 2020-10-14 주식회사 제놉시 Cfdna를 이용한 대장암 진단방법
KR20230020110A (ko) 2021-08-03 2023-02-10 충남대학교병원 대장암 예후 예측용 조성물 및 이의 응용

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102178432B1 (ko) * 2019-05-13 2020-11-13 연세대학교 산학협력단 침윤성 뇌암의 진단용 조성물
KR102499891B1 (ko) * 2022-12-01 2023-02-16 서울대학교병원 염증성 장질환 진단용 바이오마커 조성물 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177615A1 (fr) * 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procédé pour une identification large du génome de séquences régulatrices de l'expression et utilisation de gènes et de molécules dérivées pour le diagnostic et le traitement de maladies métaboliques et/ou tumorales
WO2015066442A1 (fr) * 2013-11-01 2015-05-07 Everon Biosciences, Inc. Cibles moleculaires pour l'eradication selective de cellules senescentes
WO2015108328A1 (fr) * 2014-01-14 2015-07-23 주식회사 엘지생명과학 Nouveau gène de fusion ntrk1 comme marqueur du cancer colorectal et application associée
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Machesky et al., FBBS Letters 582, 2102-2111 (2008)*
SLATTERY et al, Genes, Chromosomes & Cancer, 54권, 페이지 527-541 (2015.07.08.)*

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200117913A (ko) * 2019-04-05 2020-10-14 주식회사 제놉시 Cfdna를 이용한 대장암 진단방법
KR102526913B1 (ko) 2019-04-05 2023-05-02 주식회사 제놉시 Cfdna를 이용한 대장암 진단방법
KR20230020110A (ko) 2021-08-03 2023-02-10 충남대학교병원 대장암 예후 예측용 조성물 및 이의 응용

Also Published As

Publication number Publication date
KR20170141951A (ko) 2017-12-27
WO2017217807A2 (fr) 2017-12-21
WO2017217807A3 (fr) 2018-02-01
WO2017217807A9 (fr) 2018-03-22

Similar Documents

Publication Publication Date Title
JP7330235B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
JP6430560B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
JP2016525883A (ja) 腺癌を予後的に分類及び治療する方法
KR101925125B1 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
CN114177166A (zh) 结肠癌的治疗和诊断
Liu et al. TUG1 long non‐coding RNA enlists the USF1 transcription factor to overexpress ROMO1 leading to hepatocellular carcinoma growth and metastasis
JP2022505327A (ja) Ｓｙｔ１１抑制剤を有効成分として含む胃癌治療用組成物
US10247732B2 (en) Materials and methods for diagnosing and predicting the course of prostate cancer
CN112626207A (zh) 一种用于区分非侵袭性和侵袭性无功能垂体腺瘤的基因组合
EP3460476B1 (fr) Composition de biomarqueur comprenant lrp-1 en tant que principe actif pour le diagnostic du cancer résistant à l'irradiation ou la prédiction du pronostic d'une radiothérapie
JP7167263B2 (ja) Ｐｍｖｋを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物
KR20170052454A (ko) 소라페닙 민감성 예측용 바이오마커 조성물
US10316319B2 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
US20120156681A1 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
Andrén-Sandberg Pancreatic cancer: Animal model and molecular biology
US20240102105A1 (en) Biomarker for predicting responsiveness to anticancer agent and use thereof
KR101150410B1 (ko) 간암 진단용 마커로서의 ｓ100ｐ의 용도
EP3358012A1 (fr) Prévention, diagnostic et traitement du cancer surexprimant le gpr160
Zhu et al. LncRNA HCG11 suppresses the progression of breast cancer through cooperating with miR-330-3p/FOXO1 axis
KR20230010414A (ko) Csde1을 유효성분으로 포함하는 삼중음성유방암 전이 예측용 바이오마커 조성물
Segara Studies of retinoic acid signalling in pancreatic cancer

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant